Scientific and Regulatory Policy Committee Points to Consider for Medical Device Implant Site Evaluation in Nonclinical Studies

Author:

O’Brien Maureen T.1ORCID,Schuh JoAnn C. L.2ORCID,Wancket Lyn M.3,Cramer Sarah D.4,Funk Kathleen A.5ORCID,Jackson Nicolette D.6ORCID,Kannan Kamala7,Keane Kevin8ORCID,Nyska Abraham9,Rousselle Serge D.4ORCID,Schucker Adrienne1,Thomas Valerie S.10ORCID,Tunev Stefan11ORCID

Affiliation:

1. Charles River Laboratories, Frederick, Maryland, USA

2. JCL Schuh, PLLC, Bainbridge Island, Washington, USA

3. Charles River Laboratories, Durham, North Carolina, USA

4. StageBio, Frederick, Maryland, USA

5. Experimental Pathology Laboratories, Sterling, Virginia, USA

6. Inotiv, Fort Collins, Colorado, USA

7. Adgyl Lifesciences Private Limited, Bangalore, India

8. Blueprint Medicines, Cambridge, Massachusetts, USA

9. Tel Aviv University, Tel Aviv, Israel

10. Merck & Co., Inc., West Point, Pennsylvania, USA

11. Medtronic plc, Santa Rosa, California, USA

Abstract

Nonclinical implantation studies are a common and often critical step for medical device safety assessment in the bench-to-market pathway. Nonclinical implanted medical devices or drug-device combination products require complex macroscopic and microscopic pathology evaluations due to the physical presence of the device itself and unique tissue responses to device materials. The Medical Device Implant Site Evaluation working group of the Society of Toxicologic Pathology’s (STP) Scientific and Regulatory Policy Committee (SRPC) was tasked with reviewing scientific, technical, and regulatory considerations for these studies. Implant site evaluations require highly specialized methods and analytical schemes that should be designed on a case-by-case basis to address specific study objectives. Existing STP best practice recommendations can serve as a framework when performing nonclinical studies under Good Laboratory Practices and help mitigate limitations in standards and guidances for implant evaluations (e.g., those from the International Organization for Standardization [ISO], ASTM International). This article integrates standards referenced by sponsors and regulatory bodies with practical pathology evaluation methods for implantable medical devices and combination products. The goal is to ensure the maximum accuracy and scientific relevance of pathology data acquired during a medical device or combination drug-device implantation study.

Publisher

SAGE Publications

Subject

Cell Biology,Toxicology,Molecular Biology,Pathology and Forensic Medicine

Reference51 articles.

1. FDA.gov. How to determine if your product is a medical device. Accessed August 10, 2020. https://www.fda.gov/medical-devices/classify-your-medical-device/how-determine-if-your-product-medical-device.

2. FDA. Frequently asked questions about combination products. Accessed November 29, 2020. https://www.fda.gov/combination-products/about-combination-products/frequently-asked-questions-about-combination-products.

3. Compilation of International Standards and Regulatory Guidance Documents for Evaluation of Biomaterials, Medical Devices, and 3-D Printed and Regenerative Medicine Products

4. What Is “Preclinical Device Pathology”: An Introduction of the Unfamiliar

Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3